Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $1.27, $0.31 better than the analyst estimate of $0.96. Revenue for the quarter came in at $290 million versus the consensus estimate of $251.06 million.

GUIDANCE:

Halozyme Therapeutics sees FY2024 EPS of $4.00-$4.20, versus the consensus of $3.96. Halozyme Therapeutics sees FY2024 revenue of $900-1020 million, versus the consensus of $983.9 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.